Bausch + Lomb Co. (NYSE:BLCO – Get Rating) gapped down prior to trading on Monday . The stock had previously closed at $17.17, but opened at $16.43. Bausch + Lomb shares last traded at $17.17, with a volume of 58,809 shares changing hands.
Analysts Set New Price Targets
BLCO has been the subject of a number of recent research reports. Guggenheim initiated coverage on Bausch + Lomb in a report on Tuesday, May 31st. They issued a “buy” rating and a $24.00 price objective for the company. Royal Bank of Canada decreased their price objective on Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating for the company in a report on Sunday, July 31st. Bank of America initiated coverage on Bausch + Lomb in a report on Tuesday, May 31st. They issued a “buy” rating for the company. Wells Fargo & Company began coverage on Bausch + Lomb in a report on Tuesday, May 31st. They issued an “overweight” rating and a $23.00 price objective for the company. Finally, JPMorgan Chase & Co. began coverage on Bausch + Lomb in a report on Tuesday, May 31st. They set a “neutral” rating and a $20.00 price target for the company. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $23.23.
Bausch + Lomb Trading Up 0.3 %
The company has a 50-day moving average price of $15.71. The company has a current ratio of 1.57, a quick ratio of 1.10 and a debt-to-equity ratio of 0.35.
Hedge Funds Weigh In On Bausch + Lomb
Bausch + Lomb Company Profile
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.
- Get a free copy of the StockNews.com research report on Bausch + Lomb (BLCO)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.